Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bispecific antibodies
Pharma
Ivonescimab tops Keytruda with strong OS in PD-L1-high NSCLC
Ivonescimab delivered a particularly strong OS benefit in PD-L1-high patients, for whom Keytruda monotherapy remains the standard of care globally.
Angus Liu
Sep 13, 2026 8:00am
Amgen’s Imdelltra scores overall survival win in first-line SCLC
Sep 8, 2026 11:42am
Akeso, Summit’s ivonescimab hits OS goal in Keytruda head-to-head
Sep 3, 2026 10:29am
Akeso CEO touts biliary tract win, counters ivonescimab debate
Aug 26, 2026 11:11am
Jazz’s Ziihera nets FDA nod in first-line HER2+ stomach cancer
Aug 25, 2026 11:06am
J&J bispecific combo delivers 89% PFS benefit in myeloma
Jul 23, 2026 8:30am
